We are live on ! Find out more
XTLB

XTL Biopharmaceuticals
XTLB

4 hedge funds and large institutions have $1.05M invested in XTL Biopharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

0.45% less ownership

Funds ownership: 8.73% → 8.27% (-0.45%)

20% less capital invested

Capital invested by funds: $1.31M → $1.05M (-$261K)

33% less funds holding

Funds holding: 6 → 4 (-2)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

Holders
4
Holders Change
-2
Holders Change %
-33.33%
% of All Funds
0.06%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$1.61K

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$64K
2
Morgan Stanley
Morgan Stanley
New York
-$4.42K

XTLB Hedge Fund Activity: Q1 2022 in Review

4 of the 6,361 institutional investors tracked by Wall St. Rank reported a position in XTL Biopharmaceuticals (XTLB) for Q1 2022, worth a combined $1.05M — down 20% from $1.31M a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of XTLB and 0 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 1 added.

The largest buyer was UBS Group, adding an estimated $1.61K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $64K sold.

  • 4 institutional investors held XTL Biopharmaceuticals (XTLB) as of Q1 2022, down from 6 in Q4 2021.
  • Funds reported $1.05M of XTL Biopharmaceuticals stock for Q1 2022, down 20% quarter-over-quarter.
  • 0 funds opened new XTL Biopharmaceuticals positions in Q1 2022 and 2 closed out, a net change of -2 holders.
  • The largest XTL Biopharmaceuticals buyer in Q1 2022 was UBS Group, an estimated $1.61K added.
  • The largest XTL Biopharmaceuticals seller in Q1 2022 was Renaissance Technologies, an estimated $64K sold.

Based on aggregated 13F filings for Q1 2022.